These experiments were designed to test Pettigrew's (1979, 1983, and see below) hypothesis that plasticity in the visual cortex requires cortical norepinephrine (NE). Kittens were treated with various doses of intraventricular 6-hydroxydopamine (iOHDA) or vehicle solution. Cortical NE content was measured with high-performance liquid chromatography with electrochemical detection. We sutured the right eyes of some kittens approximately 6 weeks of age for 1 week and recorded from the left visual cortex of these kittens at the end of the week of suture. We measured the ability of the deprived eye to drive cortical cells in animals that received either 0.2 or 4.8 mg of 6-OHDA, and also in control animals that received only vehicle solution. We concluded that a particular dose of 6-OHDA decreased plasticity if it increased (relative to controls) the ability of the deprived eye to drive cortical cells. Doses of L-OHDA as small as 0.2 mg were sufficient to produce approximately maximal depletion of NE but did not decrease cortical plasticity. Doses of 4.8 mg or more did decrease cortical plasticity, although not as much as was reported by Kasamatsu and Pettigrew. We conclude that 6-OHDA can alter cortical plasticity but the decrease in plasticity does not result from NE depletion.
These experiments were designed to test Pettigrew's (1979, 1983 , and see below) hypothesis that plasticity in the visual cortex requires cortical norepinephrine (NE). Kittens were treated with various doses of intraventricular 6-hydroxydopamine (iOHDA) or vehicle solution. Cortical NE content was measured with high-performance liquid chromatography with electrochemical detection. We sutured the right eyes of some kittens approximately 6 weeks of age for 1 week and recorded from the left visual cortex of these kittens at the end of the week of suture. We measured the ability of the deprived eye to drive cortical cells in animals that received either 0.2 or 4.8 mg of 6-OHDA, and also in control animals that received only vehicle solution. We concluded that a particular dose of 6-OHDA decreased plasticity if it increased (relative to controls) the ability of the deprived eye to drive cortical cells. Doses of L-OHDA as small as 0.2 mg were sufficient to produce approximately maximal depletion of NE but did not decrease cortical plasticity. Doses of 4.8 mg or more did decrease cortical plasticity, although not as much as was reported by Kasamatsu and Pettigrew. We conclude that 6-OHDA can alter cortical plasticity but the decrease in plasticity does not result from NE depletion.
In 1963, Wiesel and Hubel found that if a kitten is reared with one eye shut, almost all cells in the visual cortex respond only to visual stimulation of the nondeprived eye. In contrast, over 80% of the cells in a normally reared kitten are binocularly driven. Subsequently, Kasamatsu and Pettigrew (1976) reported that this effect of monocular deprivation (MD) could be prevented by treating the visual cortex with 6-hydroxydopamine (6-OHDA). Two ways of administering the 6-OHDA were effective; either it could be given intraventricularly or it could be infused into a small area of cortex with an osmotic pump. Because 6-OHDA destroys catecholamine terminals, Kasamatsu and Pettigrew suggested that norepinephrine (NE) was required for plasticity in the visual cortex; that is, in the absence of NE the cortex did not change in response to the visual environment (Kasamatsu, 1983; Kasamatsu and Pettigrew, 1979) . This interpretation was supported by the finding that exogenous NE restored plasticity (Kasamatsu, 1983; .
These experiments have sparked two sorts of controversy: (1) Some laboratories have been unable to replicate all the effects reported by Pettigrew (1976, 1979) . Daw et al. (1984b Daw et al. ( , 1985 and Adrien et al. (1982) reported that intraven-tricular 6-OHDA did not decrease the effects of MD on ocular dominance. Several laboratories have, however, confirmed that local infusion of 6-OHDA is effective Daw et al., 1983a) . (2) Methods of depleting NE that do not use intracranial 6-OHDA do not decrease plasticity. This finding has thrown doubt on Kasamatsu et al.'s (198 1) conclusion that "A high level of plasticity is therefore correlated with the availability of NE . . . ." Bear and his colleagues depleted NE in newborn kittens, whose blood-brain barrier had not yet developed, with intraperitoneal injection of 6-OHDA. Daw et al. (1983b Daw et al. ( , 1984a Daw et al. ( , 1985 depleted NE either by cutting the dorsal noradrenergic bundle or by subcutaneous injection of the specific NE neurotoxin, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4). None of these procedures decreased plasticity.
The experiments reported here began by repeating the original observation of Pettigrew (1976, 1979) that intraventricular 6-OHDA decreases plasticity. Having replicated their result, at least partially, we attempted to test the interpretation that the decrease in plasticity is the result of NE depletion. If 6-OHDA decreases plasticity because it depletes NE, then the dose of 6-OHDA required for maximal depletion of NE should be sufficient to decrease plasticity. Kasamatsu and Pettigrew found that 6-OHDA decreases plasticity at doses of 5 mg or more. They did not determine the dose required to deplete NE. We examined the effect of the 6-OHDA dose on both NE content and the ocular dominance histogram obtained after 1 week of monocular deprivation. The results suggest that NE depletion is not responsible for the decrease in plasticity.
Materials and Methods

Experimental design
To establish a dose-response curve for the effects of 6-OHDA treatment on monoamine content, we measured cortical NE and dopamine (DA) in 97 animals, and cortical serotonin (5HT) content in 87 of these. Eighteen animals received vehicle solution alone and the remainder received one of 21 different doses of 6-OHDA, ranging from 0.00001 to 7.0 mg. All doses refer to the total amount received by each animal. Each total dose was apportioned into 3 to 13 daily doses. Cortical samples were removed between 4 and 17 d after the first 6-OHDA injection.
Forty-six of the 50 animals receiving between 0.00001 and 4.0 mg were given four injections. Three received three injections, and one five injections. Brain samples were removed on the day after the last injection, except for samples from the electrophysiology animals, which were removed at the termination of the recording session, 7 d after the last treatment. For a given dose of 6-OHDA, the time of dissection did not affect NE content.
Animals receiving exactly 4.8 mg received three, four, or six injections. The number of injections did not affect NE content. Brain samples from animals receiving three injections were removed the day after the last injection. Samples from animals receiving four or six injections were removed either the day after the last injection or 7 d later. Again, the time of dissection did not affect NE content.
Three groups of animals were used for electrophysiology: (1) animals receiving only ascorbic acid vehicle solution (control group, N = 6), (2) animals receiving exactly 0.2 mg 6-OHDA (low-dose group, N = 6), and (3) animals receiving at least 4.8 mg 6-OHDA (high-dose group, N = 10). The mean amount of 6-OHDA received by the high-dose uoup was j.3 mg f 0.87 SEM. The animals reported on by K&amatsu anh Pettigrew (1976 K&amatsu anh Pettigrew ( , 1979 received an average of ca. 12 mg 6-OHDA. Our "high-dose" group received smaller doses because we had difficulty maintaining the health of animals receiving doses greater than 5-8 mg. Five of our high-dose animals received their final injections the day before eye suture. The other five received one to four injections after suture. Tissue monoamine concentrations were determined in 17 out of the 22 animals used in the electrophysiological experiments, but none of these received more than 7.0 mg of 6-OHDA.
Drug administration 6-OHDA was dissolved in sterile water containing 0.1% I-ascorbic acid, deaerated with argon to prevent auto-oxidation, and frozen until use. All animals received drug or vehicle solution in a volume of 25-100 (pl) through a ventricular cannula. The needle extended beyond the end of the cannula by approximately 1 mm. Cannulas were implanted into the right lateral ventricle as described in Gordon et al. (in press ).
Monoamine assays
After dissection of the brain, three pairs of tissue samples, weighing 150-250 mg, were removed from each brain. One member of each pair was from the right cortex and the other was from the left cortex. One pair was from the posterior half of area 17, one was from the anterior half of area 17, and one was from parietal cortex. Samples were placed into 1.5 ml conical polypropylene tubes and frozen at -80°C until analyzed.
The catecholamines were assayed using high-performance liquid chromatography with electrochemical detection (HPLC-EC). The method described below is a modification of methods reported by Felice et al. (1978) and Davis et al. (198 1) .
Tissue samples were briefly sonicated on ice in 200 ~1 of 0.1 M perchloric acid and centrifuged at 27,000 x g for 20 min. A 100 ~1 aliquot of the supematant was transferred to a 1.5 ml microcentrifuge tube containing 2.5 ng of dihydroxybenzylamine (DHBA) as the internal standard and 25 mg of acid-washed alumina. The pH was raised to 8.6 by the addition of 1 ml of 1.5 M Tris buffer, and the catecholamines were adsorbed onto the alumina by vortexing for 1 min. The tubes were centrifuged, the supematant was aspirated off, and the alumina was washed with two 1 ml aliquots of distilled water, vortexing and aspirating to near dryness each time. Catechols were eluted by vortexing the alumina with 100 ~1 of 0.3 M perchloric acid for 1 min and then centrifuging. Increasing the concentration of perchloric acid from 0.1 to 0.3 M increases the percentage recovery of the catecholamines (Wagner et al., 1982) .
NE, DA, and DHBA were assayed by injecting 20 ~1 of the eluate onto the chromatograph (model LC-304T, Bioanalytical Systems, West Lafayette, IN). The compounds were separated on a 250 x 4.6 mm i.d. reverse-phase Cl8 (BAS Biophase, 5 pm particle size) column, with a mobile phase consisting of a buffer containing 0.1 M sodium acetate, 0.1 M citric acid, 100 mg/liter sodium octyl sulfate, 50 mg/liter disodium EDTA (adiusted to DH 4.8). and 12.5% (voVvo1) methanol. The flow rate was 1 .?l mumin: An RP: 18 guard colimn (26 x 2 mm; Upchurch) was used to protect the main column. The detection system employed a glassy carbon electrode (model TL-5) maintained by an LC-4B amperometric controller (Bioanalytical Systems) at a potential of +0.72 V with respect to an Ag/AgCl reference electrode. Authentic samples of NE and DA were carried through the extraction procedure with the internal standard added. The tissue level of each compound was computed by the internal standard-peak height ratio method and expressed as nanograms per gram of tissue, wet weight. The efficiency of extraction was about 8 1% for NE, 83% for DA, and 84Oh for the internal standard. NE, DHBA, and DA eluted from the column with retention times of approximately 5, 8.5, and 13 min, respectively.
Serotonin (5-HT) content was analyzed by the liquid chromatographic procedure of Cassone et al. (1983) . Values reported are expressed as nanograms per gram wet weight of tissue. 
Eye sutures
The right eyes of 38-45 d old kittens were sutured shut for 7 d. The suture was performed under ketamine (30 mg/kg) and acepromazine (4 mg/kg) anesthesia, supplemented with subcutaneous lidocaine injected temporally above the upper lid and nasally below the lower lid. All animals received at least four injections of 6-OHDA or vehicle solution prior to eye suture.
Electrophysiology
In preparation for electrophysiology, animals were anesthetized with ketamine (30 mg/kg). Preparation proceeded as described in Gordon et al. (1983) except that the electrode was angled 5"-6" anteriorly. During recording, anesthesia was maintained by a respiratory mixture of 75% nitrous oxide, 23.5% oxygen, and 1.5W carbon dioxide. Expired CO, was monitored throughout and maintained between 4.2 and 4.8%. All penetrations were made on the left side of the brain, so that cells driven exclusively by the deprived eye were in ocular dominance Group 1 and cells driven exclusively by the open eye were in Group 7 (Hubel and Wiesel, 1965) . The significance level outside a small bracket indicates the result of a comparison between the two bracketed groups. The significance level outside a large bracket indicates the result of a comparison between the first and third groups. All comparisons were done using Dunn's procedure (Kirk, 1968) .
Results
Monoamine depletion
All doses of intraventricular 6-OHDA greater than or equal to 0.0001 mg caused a marked dose-dependent depletion of NE (Fig. I) . Note particularly that all doses greater than or equal to 0.2 mg produced approximately 80% depletion. These results are similar to those obtained by Petitjean et al. (1972) using different techniques.
We performed an analysis of variance and post hoc tests (t test with Dunn's correction for multiple comparisons; Kirk, 1968) on the cortical NE content of animals receiving the doses used in the electrophysiology experiments (Table 1) . Dose produced a significant effect (p < 0.01). Animals in both the lowand high-dose groups were significantly more depleted of NE than were controls, but the effects of low and high doses on NE content were not significantly different from each other. Seventeen of the 56 animals used in this analysis were also used in the electrophysiology experiments (Fig. 1, inset) . A repeat of the ANOVA, using only these animals, supported the same conclusion: both low and high doses produced significant (p < 0.01) and similar depletion of NE.
We also analyzed the effect of sample location, using these same three groups of animals. We took samples from regions approximating posterior visual cortex, anterior visual cortex, and parietal cortex. Sample location did not affect NE values (Table 2) . Similarly, although all cannulas were implanted into the right lateral ventricle, NE values were similar in samples taken from both hemispheres ( Table 2) .
All doses of 6-OHDA tested depleted DA by about 50% (Fig.   2 ), but the amount of depletion did not appear to be dosedependent. Again, we performed an ANOVA on the cortical DA content of animals receiving the doses used in the electrophysiology experiments. Dose did not produce a significant effect on depletion (p > 0.05). The same is true if we consider only the animals actually used in the electrophysiology experiments (inset, Fig. 2 ). The effect of 6-OHDA on 5-HT content is less straightforward. Very low doses (10.00625 mg) seemed to deplete 5-HT by about 50%, while higher doses had no effect (Fig. 3) . Although additional experiments are needed to clarify this result, they would not affect the conclusions drawn here, since 6-OHDA did not significantly affect 5-HT content in the three groups of animals used in the electrophysiology experiments (F = 1.63, p > 0.10) (Fig. 3, inset) .
Ocular dominance
The ocular dominance histograms from the control, low-dose, and high-dose groups all showed a marked dominance of the nondeprived eye, but the high-dose group appeared to have more cells driven by the deprived eye than did the low-dose group or the control group (Fig. 4) .
In order to compare the groups quantitatively, we computed, for each animal, three measures of plasticity: the percent of cells driven by the deprived eye, weighted binocularity, and weighted shift to deprived eye (Kasamatsu et al., 1981) . These measures provided one data point per animal rather than one data point per cell. Cells recorded sequentially from a single animal cannot be considered independent observations. To compute weighted binocularity, we first calculated the proportion of the cells in each ocular dominance group. Each proportion was then multiplied by a weighting factor, and the results of these multiplications were added together. For Groups 1 and 7, the weighting factor was 0; for Groups 2 and 6 it was x; for Groups 3 and 5 it was %; and for Group 4 it was 1. Weighted shift to deprived eye was computed similarly except that the weighting factor for Group 1 was 1, for Group 2, '4; for Group 3, %; and so on until it reached 0 for Group 7.
Regardless of which measure was used, the low-dose and control groups were similar and the high-dose group appeared partially protected from the effects of monocular deprivation (Fig. 5) . Analyses of variance and post hoc tests confirm these conclusions ( Table 1) .
As long as an animal received at least 4.8 mg of 6-OHDA, the decrease in plasticity was not markedly dose-dependent. The average percentage of cells driven from the deprived eye was 31 +_ 11 in the four kittens receiving precisely 4.8 mg and 41 f 5 in the six kittens receiving more than 4.8 mg. The average 6-OHDA dose received by the latter six animals was 9.0 w.
To find out if the amount of plasticity in individual animals is related to residual cortical NE, we calculated correlation coefficients between NE content and each of our three measures of plasticity, using the data from the low-and high-dose groups. Confirming the information in Figure 5 , none of these correlations was statistically significant (p > 0.20 for all three correlations).
Both of these analyses indicate that NE depletion is not reTota\ Dose 6-OHOA (mgl sponsible for decreases in plasticity. A dose of 0.2 mg is sufficient to cause approximately maximal NE depletion, but is not sufficient to decrease plasticity (Fig. 5) . Clearly, the 6-OHDA doseresponse curve for depletion does not match the 6-OHDA doseresponse curve for protection from plasticity. In addition, a decrease in plasticity is not significantly correlated with residual NE content. nificantly between the three groups ( Table 3 ), suggesting that the direction of electrode travel bore approximately the same relation to the cortical surface in all three groups. The distances over which we found active cells were similar in all three groups (Table 3 ), suggesting that the penetrations in some groups were not perpendicular to the cortical surface, but down the medial bank (approximately parallel to cortical surface). In 11 out of 26 penetrations (three in the controls, four in the low-dose group, and four in the high-dose group), we recorded visually responsive cells over a distance of 2.5 mm or more, suggesting that at least these penetrations went down the medial bank and were not parallel to ocular dominance columns. Discussion High doses of 6-OHDA (4.8 mg or more) depleted cortical NE and decreased plasticity in the visual cortex. Lower doses (0.2 mg) also depleted NE, but did not decrease plasticity. Because ocular dominance was determined by listening to action potentials on a loudspeaker, the assignment of cells to groups could have been affected by inadvertent bias. To see what effect this would have on our conclusions, we reanalyzed the data under the assumption that, in the high-dose animals, all cells in Groups l-6 were incorrectly placed one ocular dominance group to the right of where they actually belonged, that is, they were assigned more deprived eye activity than they deserved. We do not think cells could be misassigned by more than one group, because two independent observers almost never disagreed by more than one group when assigning a cell to an ocular dominance category. We then "corrected" this "misassignment" by moving all Group 6 cells to Group 7, all Group 5 cells to Group 6, and so on, until we had moved Group 1 cells to Group 2. Finally, we repeated our comparisons of the control, low-dose, and high-dose groups. Although the results of the statistical tests have changed slightly, the high-dose group is still clearly different from the other two groups, and the controls and low-dose group are still not different from each other (Table 4) .
Penetration analyses
Another reason for thinking that bias did not affect our results stems from the fact that when we recorded from the low-dose group, we already knew that 0.2 mg 6-OHDA produced approximately maximal NE depletion. We also knew that 4.8 mg produced both NE depletion and decreased plasticity. Therefore, we expected that the low-dose group would also show decreased plasticity. The results obtained were contrary to our expectation.
Sampling errors could have been a problem if most electrode penetrations had been perpendicular to ocular dominance columns in some groups of animals, but parallel to ocular dominance columns in other groups. We do not have histological reconstructions of our electrode tracks to provide information about the direction of electrode travel because we used the cortex of both hemispheres for HPLC. (We did not save one hemisphere for electrode localization because we were not certain that injecting 6-OHDA into one lateral ventricle would produce uniform depletion bilaterally.) However, the number of cells and range of orientations encountered/mm electrode travel were similar in all three groups, suggesting that we sampled orientation columns uniformly in all three groups. Because ocular dominance columns and orientation columns are both perpendicular to the cortical surface Wiesel, 1965, 1977) we surmise that we also sampled ocular dominance columns uniformly in each group. Our lack of histology also means that we cannot be certain that the proportion of cells recorded from each cortical layer was the same in each group of animals. In MD animals not treated with 6-OHDA, the percentage of cells driven by the deprived eye may have been somewhat greater in layers I-IV than in layers V and VI (Shatz and Stryker, 1978, Fig. 3 ). We do not think the putative effect of high doses of 6-OHDA is an artifact of encountering more cells from the upper layers in the high-dose animals. We draw this conclusion because Shatz and Stryker (1978) reported that most of the cells driven by the deprived eye were driven only by this eye. In our high-dose animals, most of the cells driven by the deprived eye were binocularly driven.
The maximal NE depletion was about 80%. We do not know the location or origin of the remaining 20%. We do not think the residual NE maintained normal plasticity in the low-dose animals because high-dose animals had similar residual NE yet showed decreased plasticity. Pettigrew's (1976, 1979) reports that 6-OHDA treatment decreases plasticity in the kitten visual cortex have been controversial. All experiments confirming their conclusion have applied 6-OHDA intracortically Daw et al., 1983a Daw et al., , 1985 . The results of experiments using intraventricular 6-OHDA have caused dissension (Adrien et al., 1982; Daw et al., 1985) .
Ours is the first report to confirm, even qualitatively, Pettigrew's (1976, 1979) original observation that intraventricular 6-OHDA treatment decreases cortical plasticity. The decrease in plasticity that we observed was, however, considerably smaller than that reported by Kasamatsu and Pettigrew (1979, Fig. 6) . Although the average 6-OHDA dose in our high-dose group was considerably smaller than the average dose used by Kasamatsu and Pettigrew (1979) , we do not think this explains our smaller effect, because the percentage of binocular cells in animals receiving more than 4.8 mg was not significantly greater than the percentage of binocular cells in animals receiving precisely 4.8 mg. Figure 6 compares the reports of four laboratories on the effects of intraventricular 6-OHDA treatment. Compared to other investigators, Kasamatsu and Pettigrew (1979) found more cells driven by the deprived eye in both 6-OHDA-treated animals and in controls. The data collected by Daw's group (Daw et al., 1985) are very similar to ours, yet Daw's group concluded that intraventricular 6-OHDA treatment did not decrease plasticity. We drew the opposite conclusion, probably because we ran six rather than three control animals, and thus had enough data to find statistically significant differences among the various groups on all three measures of deprived eye effectiveness. Adrien et al. (1982) ran only one control animal and found that it was not different from the three 6-OHDA-treated animals. They, too, concluded that 6-OHDA treatment did not decrease plasticity. Given that the increase in plasticity is modest compared to that reported by Pettigrew (1976, 1979) experiments using fewer than five animals per group are unlikely Trombley et al. Vol. 6, No. 1, Jan. 1986 I 3 Kosamatsu Dow Adrien Figure 6 . Comparison of the data obtained by four different laboratories in response to intraventricular treatment with 6-OHDA. (The data from Daw's laboratory include only cells recorded contralateral to the deprived eye.) Each laboratory is indicated by the first author of the paper from which the data were taken (Trombley et al., the present study; Kasamatsu and Pettigrew, 1979; Daw et al., 1985; Adrien et al., 1982) . Hatched bars. Data from control animals; open bars, data from animals treated with more than 4 mg of 6-OHDA. A-C, Three different measures of the effects of 6-OHDA treatment (see text for definitions). The number of animals in each group is indicated at the top of thefgure. The asterisks on the ordinates are values computed after summing the histograms from a normal 45 d old kitten (Olson and Freeman, 1975) and from a normal 38 d old kitten (Blakemore and Van Sluyters, 1975) .
to find significant differences between 6-OHDA-treated animals and vehicle-treated animals. We think that the decrease in plasticity does not result from NE depletion. Although 0.2 mg of 6-OHDA caused approximately maximal NE depletion, it failed to decrease plasticity.
Other investigators, depleting NE by a variety of techniques, have also failed to support the hypothesis that NE is required for plasticity Daw et al., 1984b Daw et al., , 1985 .
If NE depletion is not responsible for the decrease in plasticity following 6-OHDA, what is? One hypothesis is that 6-OHDA alters noradrenergic receptor density. This hypothesis is suggested by the finding that 6-OHDA treatment causes supersensitivity in both alpha and beta noradrenergic receptors in rat cortex (Harden et al., 1977; Reader and Briere, 1983; Spom et al., 1976; U'Prichard et al., 1979 U'Prichard et al., , 1980 . Beta receptors may be specifically involved, propanalol, a beta blocker, both decreases plasticity and causes supersensitivity of beta receptors (Kasamatsu, 1979; Minneman, 1982) . Supersensitivity can probably be produced by more than one mechanism. Dopaminergic supersensitivity induced by DA postsynaptic receptor blockade is additive with supersensitivity produced by 6-OHDA treatment, suggesting that monoamine depletion alone is not sufficient to produce maximal supersensitivity (Staunton et al., 1982) . Perhaps 6-OHDA has several effects on NE receptors. While the effect of decreased transmitter availability is apparent at low doses, the other effect(s) may require higher doses. We do not know how receptors are affected at higher doses, but Bylund and Snyder (1976) indicate that 6-OHDA does not block beta receptors. While we have found no evidence that 6-OHDA binds to alpha receptors, this possibility should be tested. Alternatively, the effect of 6-OHDA on plasticity may not be a specific effect on the NE system. The literature abounds with manipulations affecting plasticity. Shaw and Cynader (1984) found that intracortical infusion of L-glutamate decreased plasticity and suggested that any manipulation changing the signalto-noise ratio in the visual cortex would produce this effect.
Others have suggested that ocular motility and extraocular afferents are important (Buisseret et al., 1978; Crewther et al., 1978; Freeman and Bonds, 1979) . Still others have reported that activity in the intralaminar nuclei of the thalamus and the mesencephalic reticular formation affects plasticity (Singer, 1982; Singer and Rauschecker, 1982) . Since we do not understand the cellular changes underlying any of these effects on plasticity, we do not know whether they share a common mechanism.
In view of the present results, an investigation of changes in noradrenergic receptors following 6-OHDA treatment seems to be a logical next step in elucidating the effects of 6-OHDA on plasticity. If similar doses of 6-OHDA are required to produce changes in receptors and changes in plasticity, two more questions become pertinent. First, do methods of depleting NE that fail to alter plasticity also fail to alter receptor function? Second, do the myriad other manipulations reported to produce changes in plasticity also produce changes in noradrenergic receptors?
